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Little is known about potentially modifiable factors in Ebola 
virus disease in children. We undertook a retrospective co-
hort study of children <13 years old admitted to 11 Ebola 
holding units in the Western Area, Sierra Leone, during 
2014–2015 to identify factors affecting outcome. Primary 
outcome was death or discharge after transfer to Ebola 
treatment centers. All 309 Ebola virus–positive children 2 
days–12 years old were included; outcomes were avail-
able for 282 (91%). Case-fatality was 57%, and 55% of 
deaths occurred in Ebola holding units. Blood test results 
showed hypoglycemia and hepatic/renal dysfunction. Death 
occurred swiftly (median 3 days after admission) and was 
associated with younger age and diarrhea. Despite trian-
gulation of information from multiple sources, data avail-
ability was limited, and we identified no modifiable factors 
substantially affecting death. In future Ebola virus disease 
epidemics, robust, rapid data collection is vital to determine 
effectiveness of interventions for children.
The Ebola virus disease (EVD) outbreak in West Af-rica during 2014–2016 comprised ≈28,600 cases and 
claimed ≈11,300 lives (1). The case-fatality rate (CFR) was 
high for Ebola virus (EBOV)–infected children <5 years of 
age (2–4). Outbreak conditions with overstretched health 
systems and paucity of data has meant there is little under-
standing of how modifiable clinical management, opera-
tional-, and response-specific factors might have affected 
outcomes of children with EVD (3,5).
During the outbreak, several different health service 
models for managing suspected EVD cases evolved. In 
the highly populated Western Area of Sierra Leone, in-
cluding Freetown, on-site Ebola holding units (EHUs) 
were set up at health facilities. Their goal was to enable 
provision of normal healthcare to continue by screen-
ing patients before entry (6). Patients fulfilling screening 
criteria were admitted to the on-site EHUs for EVD test-
ing. Persons testing positive for EBOV were transferred 
to Ebola treatment centers (ETCs). At the height of the 
outbreak, laboratory, ambulance, and bed capacities were 
overwhelmed, leading to substantial delays throughout 
the pathway, limited provision of clinical care, and long 
transfer distances (7,8). As the response scaled up, delays 
shortened and transfer distances decreased as more ETCs 
opened locally (7,8). These changing health systems fac-
tors possibly affected death and are amenable to modifica-
tion in future outbreaks.
Patient data were collected on paper forms at EHUs 
and ETCs. Basic demographic and initial symptom infor-
mation was telephoned to regional control centers for en-
try into electronic databases and transfer to international 
nongovernment organizations for epidemiologic surveil-
lance (3,5,9,10). However, data on clinical management 
and key factors, such as caregiver accompaniment, were 
not included. Furthermore, communication between 
EHUs and ETCs was limited, meaning EHUs had no in-
formation about patient outcome after transfer, and data 
from ETCs were subject to substantial survivorship bias 
(11–13). Attempts to link clinical management data be-
tween sites were limited.
We describe the clinical features, management, and 
outcomes of children with EVD from initial presentation 
to final outcome. We also explore risk factors for death, in 
particular factors amenable to modification.
Methods
Study Population and Setting
All children <13 years of age admitted to 11 EHUs in the 
Western Area from August 14, 2014, through March 31, 
2015, were eligible for inclusion, anticipating that the dis-
ease phenotype in adolescents might be similar to that in 
adults and that some factors (e.g., caregiver accompaniment) 
were more relevant for younger children (3,14). Patients 
were screened for EVD symptoms or contact with EBOV on 
entry to healthcare facilities. Patients whose signs and symp-
toms fulfilled the World Health Organization definition for a 
suspected case were admitted to on-site EHUs to have blood 
taken for EBOV PCR testing (online Technical Appendix 
Figure, http://wwwnc.cdc.gov/EID/article/22/10/16-0579-
Techapp1.pdf) (15). Basic demographic data were reported 
to the Western Area Emergency Response Command Centre 
(WAERC). Samples were transported to specialist laborato-
ries, which were usually off-site. Patients testing negative for 
EVD were discharged home or admitted to a routine (non-
Ebola) hospital bed (Figure 1) (8). Patients testing positive 
were transferred to an ETC coordinated by the WAERC. Oc-
casionally, if ETCs were full, a patient might stay at an EHU 
for the duration of illness and be discharged home directly.
Medical care varied among EHUs according to staff-
ing capabilities and facilities available. The Sierra Leone 
Ministry of Health recommended that all patients admitted 
to an EHU receive antimalarial drugs and broad-spectrum 
antimicrobial therapy (15,16). Until late December 2014, 
most EHUs abstained from taking blood for tests other 
than EBOV PCR (WAERC, November 2014, unpub. data). 
Treatment was primarily supportive; some units operated 
a no-needle policy, providing only oral rehydration salt 
(ORS) solution and oral medications. Most units did not 
allow asymptomatic caregivers to enter an EHU high-risk 
area (i.e., Red Zone) with their children, because of the po-
tential risk for nosocomial EBOV infection, so many chil-
dren were admitted alone.
Data Collection
Data stored electronically in the WAERC database in-
cluded demographics and symptoms at presentation. 
To obtain more detailed data, we visited 11 EHUs, Ola 
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During Children’s Hospital, and the Western Area ETCs 
(Figure 2) to extract data from paper records, including de-
mographic data; contact histories; clinical features at and 
during admission; treatment received; laboratory results; 
and health system factors, such as duration of transfer to 
ETC and outcome (death or survival to discharge) (online 
Technical Appendix Table 1). This information was sup-
plemented by interviews with staff members, in particu-
lar about caregiver accompaniment, which was routinely 
documented only at 1 site. Information about outcomes 
after discharge was obtained from 2 survivor clinics in 
the Western Area and telephone calls to guardians. Data 
were cross-referenced with the WAERC database, test re-
sults from regional laboratories, child protection records, 
districtwide burial records, and the telephone service set 
up for community ambulance notification (online Tech-
nical Appendix Table 1). We developed a scheme to 
ensure consistency in matching records from different 
sources (online Technical Appendix). Data were entered 
directly into a password-protected database (Epi Info ver-
sion 7.1.4; Centers for Disease Control and Prevention, 
Atlanta, GA, USA). Personal identifiers were removed 
before analysis.
Outcome and Potential Risk Factors
Possible outcomes were death (recorded at EHU or ETC) 
or survival (recorded as discharge from ETC or EHU). We 
considered variables encoding potential risk factors for out-
come, including demographics (age, sex); duration from 
symptom onset to EHU arrival; symptoms at presentation; 
receipt of antimicrobial drugs, antimalarial drugs, or intra-
venous fluids at EHU; specific EHU attended; period in the 
epidemic (before or on/after January 9, 2015, when bed ca-
pacity first outstripped demand in the Western Area [8]); 
and whether the child was admitted alone, unaccompanied 
by a caregiver (online Technical Appendix).
We restricted a separate analysis to children transferred 
to ETCs. Variables were days from EHU admission to 
ETC transfer, transfer distance, ETC attended, and receipt 
of medications or intravenous fluids at the ETC. If health 
information was available for survivors after discharge, it 
was collected but was not a primary focus of this study.
Sample Size
At study conception in December 2014, we estimated 300 
children would have sought care in Western Area EHUs. 
We aimed to obtain data on all these children (see calcula-
tions in online Technical Appendix).
Statistical Analysis and Ethical Considerations
We conducted a descriptive analysis on all children ad-
mitted to EHUs. Among children with known outcome, 
we conducted univariable and multivariable analyses to 
explore factors potentially affecting outcome (online 
Technical Appendix). We accounted for missing data 
with multiple imputation using chained equations (online 
Technical Appendix) (17). All analyses were conducted 
by using Stata version 14.0 (StataCorp LP, College Sta-
tion, TX, USA). We obtained approval from the Sierra 
Leone Ethics and Scientific Review Committee and the 
London School of Hygiene and Tropical Medicine Ethics 
committee (ref. 8924).
Results
Overall Outcomes
Our study comprised all 309 children 2 days–12 years of 
age admitted to EHUs and testing positive for EBOV (me-
dian age 6 years, interquartile range [IQR] 3–10 years; 158 
[51%] female). Outcome (death or discharge) was avail-
able for 282 (91%) children; CFR was 57% (95% CI 51%– 
63%) (Table 1, http://wwwnc.cdc.gov/EID/article/22/10/16-
0579-T1.htm). Eighty-six (28%) children died at EHUs, and 
223 (72%) were transferred to ETCs, where an additional 74 
(24%) died. Therefore, 55% of deaths occurred at EHUs and 
45% at ETCs (Figure 3, panel A). Of children transferred to 
ETCs, 116 (38%) were discharged home and 3 (1%) were 
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Figure 1. Patient care pathway of EHUs, Western Area (including 
Freetown), Sierra Leone, August 2014–March 2015. The OICC 
was set up to care for children with substantial Ebola virus 
exposure (usually a first-degree relative with confirmed EVD) and 
without relatives to care for them during the 21-day incubation 
period. Figure reproduced from (8) (Creative Commons License). 
EHU, Ebola holding unit; EVD, Ebola virus disease; OICC, 
observational interim care center.
RESEARCH
discharged to a hospital (Figure 3, panel A). Three children 
were discharged home from EHUs without transfer. Median 
duration of EHU/ETC admission among children who died 
was 3 days (IQR 1–5 days) and for survivors was 17 days 
(IQR 11–20 days). Outcomes were missing for 27 (9%) chil-
dren, all of whom had been transferred out of EHUs to ETCs 
(Figure 3, panel A). The CFR was highest in September and 
October 2014, a period of intense EBOV transmission, and 
peaked again in January 2015 (Figure 3, panel B).
Clinical Features
Data were available on symptoms at presentation for ≈70% 
of children (Table 1). Fever was the most prevalent symp-
tom (99%), followed by fatigue/weakness (80%), anorexia 
(79%), vomiting (59%), and diarrhea (44%); unexplained 
bleeding was rare (1%). Median reported duration of symp-
toms before presentation was 3 days (IQR 2–4 days). Of 
193 children for whom exposure data were available, 151 
(78%) had documented prior contact with a person with 
EVD, and 42 (22%) had documentation of no prior expo-
sure to EVD.
Additional clinical information was available for a 
subset of 88 patients for the duration of EHU/ETC admis-
sion. In addition to 3 children with spontaneous bleeding 
at presentation, 7 (8%) had bleeding after admission. In 
order of frequency, manifestations were bleeding gums, 
epistaxis, hematemesis, melena, and vaginal bleeding. 
Only 1 of these 10 children survived to discharge. Seizures 
were recorded during admission in 6 (7%) children: 3 died, 
2 were discharged in a comatose state, and 1 recovered with 
no reported sequelae.
Laboratory Features
Additional blood test results were available for 36 children 
from 3 health facilities (Table 2). These children were of 
similar age (median 6 years, IQR 3–7 years) to children 
in the overall cohort, but the CFR was lower (11/36 [31%; 
95% CI 16%–48%]). Children who died were younger than 
children who survived (data not shown).
Tests were taken a median of 3 days (range 0–18 
days) after admission at an EHU. Leukocyte count (pre-
dominantly granulocytes) and C-reactive protein were 
elevated, and there was considerable renal and liver func-
tion derangement, particularly among children who died. 
Hyponatremia occurred among children who survived and 
who died, but potassium levels tended to be within normal 
limits. Hypoglycemia (blood glucose <4.0 mmol/L [refer-
ence 4–6.9 mmol/L) was common among children who 
died (55% [95% CI 23%–83%]) and who survived (30% 
[95% CI 13%–53%]).
Cycle threshold (Ct) represented the point at which a 
quantitative PCR was interpreted as positive: the lower the 
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Figure 2. Location of Ebola 
holding units (blue star) and 
Ebola treatment centers 
(red circle), Western Area, 
Sierra Leone, January 2015. 
Population density map source: 
MapAction (cited 2015 Nov 8); 
reproduced with permission. 
Population figures are projected 
for 2014 from the 2004 
census (http://www.mapaction.
org/?option=com_mapcat&view=
mapdetail&id=3589)..
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Ct, the higher the initial viral load. Results were available 
from 90 children (42 who survived; 40 who died; 8 un-
known; median age [IQR] 8.5 years [4–11 years], 5.0 years 
[3–10 years], and 6.0 years [2.9–10.5 years], respectively). 
The range of Ct was similar for children who died and who 
survived (14.3–35.8 vs. 17.0–38.2) (Table 2).
Health Systems and Clinical Management Factors
Median duration of admission at EHU before transfer or 
death was 2 days (IQR 1–3 days). Outcomes were avail-
able for 193 children who survived to transfer to an ETC. 
Twenty-five (13%) were transferred directly onto an on-
site treatment ward, but most (168 [87%]) traveled 5–380 
km (median 25 km [IQR 19.5–45.0 km]). For 201 children 
for whom information was available about caregiver ac-
companiment (written documentation in 119 [59%], infor-
mation from staff interviews alone in 84 [41%]), 74 (37%) 
were documented as unaccompanied admissions.
Treatment was primarily supportive but ranged from 
aggressive intravenous or intraosseous fluid resuscitation 
with laboratory monitoring (more common in ETCs) to 
ORS and oral medications. Medications received at either 
EHUs or ETCs were recorded for 178 (58%) children: 99% 
received antimicrobial drugs and ORS, 85% antimalarial 
drugs, and 19% intravenous fluids.
Risk Factors for Death
In univariable analysis, younger age (odds ratio [OR] per 
year of life 0.91 [95% CI 0.85–0.97]) and diarrhea at pre-
sentation (OR 1.94 [95% CI 1.11–3.39]) were significantly 
associated with death. CFR was highest for infants (70%) 
(Figure 3, panel C).
In multivariable analysis, age was the strongest pre-
dictor of death (adjusted OR 0.92 [95% CI 0.86–0.98] 
per 1-year increment in age) (Table 1; Figure 3, panel C). 
Diarrhea at presentation was associated with death (OR 
1.91 [95% CI 1.08–3.39]). None of the following were 
associated with death: time from symptom onset to EHU 
admission, receipt of specific medications or intravenous 
fluids, attendance at any particular EHU, or being accom-
panied by a caregiver (Table 1; online Technical Appendix 
Table 2). We found minimal difference between estimates 
obtained by analyzing only complete records compared 
with accounting for missing data using multiple imputation 
(online Technical Appendix Tables 3, 4).
For 193 children transferred to ETCs for whom out-
comes were known (online Technical Appendix Tables 5, 
6), neither longer duration of EHU stay before transfer nor 
longer transfer distances appeared detrimental. Outcomes 
between ETCs varied considerably, but CIs were wide. Re-
ceipt of medications or intravenous fluids at the ETC also 
were not associated with survival.
Health Status of Survivors
Of 122 surviving children, data from survivor clinics or 
telephone interviews were available for 42 (34%). Twenty-
five (60%) reported no problems; 6 (14%) were referred for 
ophthalmologic review with possible uveitis, 1 with mon-
ocular blindness; 3 (7%) had hearing problems; 2 (5%) had 
alopecia; 2 (5%) had joint pains; and 1 (2%) depressed af-
fect. Of 2 children discharged without fully recovering con-
sciousness, 1 was recovering and being cared for at home; 
the second had made little improvement in hospital.
Discussion
We aimed to identify modifiable operational and clinical 
management factors that could affect the outcome of EVD in 
children. The relative completeness of outcome data (91%) 
was possible only through a high level of collaboration 
between government and nongovernment organizations, 
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Table 2. Blood test results for children attending Ebola holding units and Ebola treatment units for whom blood test results were available, 
Western Area, Sierra Leone, August 2014–March 2015* 
Laboratory value (reference) 
Median value among patients 
who died 
Median value among patients 
who survived p value† 
Leukocyte count (4–11), × 109/L 33, n = 7 9.2, n = 22 0.067 
Lymphocyte count (1–3.2), × 109/L 6.1, n = 7 2.9, n = 21 0.007 
Granulocyte count (2.5–7.5), × 109/L 19.9, n = 7 4.9, n = 22 0.009 
Hemoglobin (135–175), g/L 123, n = 7 110, n = 22 0.097 
Platelets (150–430), × 10/L 376, n = 7 179, m = 22 0.17 
Sodium (128–145), mmol/L 127, n = 10 131, n = 24 0.11 
Potassium (3.6–5.1), mmol/L 3.9, n = 7 4.1, n = 23 0.9 
Urea (2.5–7.9), mmol/L 16.2, n = 11 4.2, n = 24 <0.001 
Creatinine (53–106), mmol/L 120, n = 10 49, n = 24 0.003 
Albumin (33–50), g/L 26, n = 11 31, n = 20 0.25 
Aspartate transaminase (11–35), U/L 2,000, n = 8 159, n = 17 0.001 
Alanine transaminase (10–48), U/L 667, n = 11 131, n = 18 <0.001 
Creatine kinase (39–380), U/L 2,544, n = 8 623, n = 18 0.13 
C-reactive Protein (0–7.5), mg/L 96, n = 10 8, n = 17 0.007 
Viral cycle threshold, range‡ 14.3–35.8, n = 40 17–38.2, n = 42 NA 
*n values indicate number of patients in category for whom value was available. NA, not applicable 
†Wilcoxon rank-sum test used because of small sample size. 
‡Different reference ranges used. 
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triangulating available data sources. This collaboration 
enabled crucial matching of clinical management data be-
tween EHUs and ETCs, which had not been undertaken 
previously. That 55% of deaths occurred in EHUs high-
lights the importance of data pooling. Data from ETCs 
alone need to be interpreted in the context of substantial 
survivorship bias (11,12,18). Patients spent a median of 2 
days at an EHU before ETC transfer, a critical period given 
the rapid progression to death.
Cohorts of children reported from previous outbreaks 
have been smaller, 1 comprising 20 laboratory-confirmed 
cases and another comprising 55 patients <22 years of age 
(4,19). The largest study of children from this outbreak was 
an international cohort documenting epidemiologic find-
ings from across the 3 most affected countries based on 
data reported to regional control centers (3). Although the 
sample size included was much larger (2,991 confirmed or 
probable cases in patients <16 years of age), outcomes were 
available for 42%–59% (varying with age), versus 91% in 
our study. Furthermore, data were not available about clini-
cal management or caregiver accompaniment.
Our study concurs with previous analyses report-
ing that young age, particularly infancy, is a risk factor 
for death from EVD (2,3,20–23). Progression to death 
was swift (median time 3 days from admission [IQR 1–5 
days]), more rapid than reported in mixed age cohorts, and 
the overall death rate was high (2,9). Compared with the 
international cohort data from this outbreak, the children in 
this cohort progressed more rapidly to death. The shortest 
mean duration from admission to death in the international 
cohort was 3.7 days for children 1–4 years of age and in 
other age groups was longer (3). Gastrointestinal symp-
toms predominated here as in mixed age cohorts, although 
diarrhea was less common in our study (45%) than in the 
international cohort study (60%) (5,13,24). Diarrhea at pre-
sentation, most likely a proxy for more severe disease, ap-
peared to nearly double the risk for death. Few other clini-
cal features at presentation appeared to be associated with 
death, possibly because of missing or unreliable data; in 
particular because so many children were unaccompanied, 
contact history, history of symptoms before attendance, and 
symptom duration must be cautiously interpreted. Contact 
history was denied in 42 (22%) children, implying a poten-
tial incentive for concealment, which further highlights the 
need for caution in interpreting these data. This study was 
powered to detect effects with an OR of ≈2, and the wide 
CIs for most risk factors mean that real associations not 
detected by this study cannot be ruled out.
Hypoglycemia in children with EVD has been as-
sumed but not previously demonstrated (15). In this co-
hort, hypoglycemia was frequent and severe (40% of chil-
dren tested had blood sugar <4.0 mmol/L). Hypoglycemia 
should be actively sought and treated as a priority, and 
dextrose should be included in maintenance intravenous 
fluids to minimize risk for hypoglycemia if monitoring is 
unavailable. The blood tests in this study were taken at 
the point of cannulation with no prior intravenous fluids 
received. As reported in a previous mixed-age cohort (12), 
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Figure 3. Outcome 
characteristics of children <13 
years of age with Ebola virus 
disease, Western Area, Sierra 
Leone, August 2014–March 
2015. A) Patient outcome 
flowchart; B) patient count and 
case-fatality rate (CFR) by 
month; C) Patient count and 
CFR by age. Error bars indicate 
95% CIs.
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other laboratory features include a dramatically raised leu-
kocyte count (predominantly neutrophils) and derangement 
of renal and liver function. These tests were conducted a 
median of 3 days after EHU admission and thus are likely 
to represent a less severe phenotype of disease than in those 
who died more rapidly. Data from 12 children <6 years of 
age in the Guinea JIKI trial also demonstrated raised serum 
creatinine, creatine kinase, and liver function enzymes, al-
though less frequently than in our study (25). In contrast, a 
study from Gulu, Uganda, found no relation between serum 
chemistry results and death, although an association was 
seen with markers of immune activation (19). A high viral 
load (low Ct on PCR) has been demonstrated to be associ-
ated with death, but because our study was multicenter, the 
tests were conducted in different laboratories using differ-
ent assays, making comparisons inappropriate (25–28).
In terms of clinical management factors, we found no 
evidence that intravenous fluids had a protective effect on 
survival, although our study lacked power for this analysis. 
A case series of adults and children in Liberia also found 
that intravenous fluids were not protective (29). This find-
ing may reflect sicker patients being prioritized for fluid 
resuscitation. However, aggressive fluid resuscitation in 
the context of limited monitoring (as was the case in most 
EHUs) may also have entailed risks. Further research into 
the safest methods of fluid resuscitation and effective fluid 
balance monitoring in the Red Zone are crucial, alongside 
accurate documentation of caregiving.
Nearly 40% of children, even infants, were admitted 
unaccompanied to EHUs. Unaccompanied children are 
vulnerable to inadequate oral fluid resuscitation and the 
hazards of high-concentration chlorine on tap or in basins 
before even considering the emotional trauma of separation 
(30,31). Furthermore, such children could contribute to 
nosocomial EBOV transmission because they are difficult 
to keep in their bed space. The heat of personal protective 
equipment meant that healthcare workers could not spend 
long within the Red Zone supervising children (30,31). 
Many units had started to have survivors work in Red 
Zones because they are understood to be at vanishingly low 
risk for re-infection (32,33). This option could be explored 
in future outbreaks to ensure adequate care for children.
The overwhelming majority (87%) of children who 
survived long enough to be moved from an EHU were 
transferred at least 5 km. Even unaccompanied children 
and young infants faced transfers up to 380 km to the near-
est available ETC bed in very basic ambulances. All of the 
children in this study who had unknown outcomes were 
transferred out of EHUs and might have been lost to their 
families in addition to epidemiologic follow up. Prioritiz-
ing transferring children to locations close to their homes 
could minimize the chance of this loss. Although in our 
study, neither caregiver presence nor transfer distance was 
significantly associated with outcome, in the interests of the 
child both issues could be planned for in future outbreaks.
Although our study has outcomes for 91% of children, 
missing data and data reliability are a limitation. Transfer-
ring information, such as patient observations and medica-
tions given in the Red Zone to the low-risk Green Zone 
where notes were kept, was challenging. Solutions varied 
from scanners or radios to shouting over the fence, but none 
were ideal. Stethoscopes were banned, and even simple 
equipment, such as weighing scales and clocks, had a lim-
ited lifespan because of the high concentrations of chlorine 
used for cleaning. Some analyses lacked power, with wide 
CIs for some risk factors. Pooling data in this study with 
other similar cohorts could help identify additional risk fac-
tors for survival.
Children have previously been relatively spared by 
EVD (20,34,35). As the West Africa epidemic progressed, 
children constituted an increasing proportion of EVD cases 
(3,36,37). It is possible that earlier in the outbreak, more 
children were dying unreported at home, given that before 
the EVD epidemic, Sierra Leone had one of the highest in-
fant mortality rates in the world (38). Thus, data presented 
here also might be subject to survivorship bias. A change 
in health-seeking behavior, namely bringing very sick chil-
dren to hospital, might have contributed to the second peak 
in CFR later in the outbreak (Figure 3, panel B). Docu-
mented duration of symptoms before attendance did not 
change over time (data not shown) but might have been 
unreliably recorded.
The overarching messages of our study are 3-fold. First, 
death rates in children were high, and children died even 
more rapidly than previously documented (3). Second is the 
apparent lack of association between death and potentially 
modifiable factors that could alter outcome after infection. 
This lack of association calls for urgent prioritization of in-
terventions targeted to prevent EVD in children. Children 
have been neglected thus far in EVD vaccine development, 
and this knowledge gap should be addressed (39,40). Fur-
thermore, children should be included as a priority in future 
clinical trials of supportive care methods and of antiviral 
drugs. Third, the paucity and quality of data and the lack 
of studies pooling clinical management data from different 
sites need to be tackled. Many records were already lost 
when this study was conducted; any available data need 
to be urgently salvaged and shared. Plans for safe, rapid, 
and accurate data collection must be prioritized in outbreak 
planning to identify simple interventions that might im-
prove outcome. We should act or miss a vital opportunity to 
learn how better to combat EVD in future epidemics.
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Ebola, previously known as Ebola hemorrhagic fever, is a rare and deadly disease caused by infection with 
one of the Ebola virus strains. Ebola can cause disease in humans and nonhuman primates (monkeys, 
gorillas, and chimpanzees).
Ebola is caused by infection with a virus of the 
family Filoviridae, genus Ebolavirus. There are five 
identified Ebola virus species, four of which are 
known to cause disease in humans. Ebola viruses 
are found in several African countries; they were 
first discovered in 1976 near the Ebola River in 
what is now the Democratic Republic of the Congo. 
Before the current outbreak, Ebola had appeared 
sporadically in Africa.
The natural reservoir host of Ebola virus remains 
unknown. However, on the basis of evidence and 
the nature of similar viruses, researchers believe 
that the virus is animal-borne and that bats are the 
most likely reservoir. Four of the five virus strains 
occur in an animal host native to Africa.
http://wwwnc.cdc.gov/eid/page/ebola-spotlight
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